Gilead Says Findings Positive From Real-World Use of Yescarta in Lymphoma

Date : 12/09/2019 @ 8:43PM
Source : Dow Jones News
Stock : Gilead Sciences Inc (GILD)
Quote : 64.67  0.84 (1.32%) @ 3:31PM

Gilead Says Findings Positive From Real-World Use of Yescarta in Lymphoma

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Gilead Sciences Charts.

By Michael Dabaie

 

Gilead Sciences Inc. (GILD) said its Kite subsidiary had positive findings from real-world use of Yescarta in relapsed or refractory large B-Cell lymphoma.

Kite and the Center for International Blood and Marrow Transplant Research unveiled the findings from an ongoing post-marketing study evaluating the safety and efficacy of Yescarta in adult patients.

In the analysis, efficacy and safety of Yescarta were comparable to that observed in the ZUMA-1 trial, despite a larger proportion of older, more difficult-to-treat patients in the real-world setting, Gilead said.

Yescarta was approved by the U.S. Food and Drug Administration in 2017 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

December 09, 2019 15:28 ET (20:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest GILD Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.